Gefitinib Plus Bevacizumab vs. Gefitinib Alone for EGFR Mutant Non-squamous Non-small Cell Lung Cancer

Background/Aim: A phase II trial was conducted to assess the efficacy and safety of gefitinib plus bevacizumab for EGFR mutation-positive non-small cell lung cancer (NSCLC). Patients and Methods: Patients were randomly assigned to receive either gefitinib at 250 mg/day alone or with bevacizumab at 1...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:In Vivo
Hoofdauteurs: KITAGAWA, CHIYOE, MORI, MASAHIDE, ICHIKI, MASAO, SUKOH, NORIAKI, KADA, AKIKO, SAITO, AKIKO M., ICHINOSE, YUKITO
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: International Institute of Anticancer Research 2019
Onderwerpen:
Research Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6506320/
https://ncbi.nlm.nih.gov/pubmed/30804129
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21873/invivo.11498
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items